Mikhail Blagosklonny on Aging and Disease Prevention

Mikhail Blagosklonny, is a scientist who studies cancer and aging. He attended the First Pavlov State Medical University of St. Peterburg to earn both his M.D. in internal medicine and Ph.D of experimental medicine and cardiology. He was a professor of oncology at Rosswell Park Institute in New York.In 2002, he was appointed the position of associate professor of medicine for the New York Medical College in Valhalla, New York. Shortly afterwards he went on to become the senior scientist at Ordway Research Institute in Albany, New York. Where he remained in this position until 2009, when Rosswell Park Cancer Institute appointed him professor of oncology.Until Mikhail Blagosklonny and his studies proved different, one could count on the fact that their body was going to age. Age in the manner of there being the occurrence of a functional decline and random molecular damage, this process is something we humans have come to accept as the normal aging process. This process of aging could not be prevented, at least until now.

The discovery of Everolimus, a rapamycin analog, was found to be the turning point in the human quest for immortality, when it was found that this drug could actually boost the immunity of old humans. This was cause for many to celebrate as the year 2014 came to a close.The hyperfunction theory gives aging the description of being a growth continuum, created by a pathway of signals called TOR (target of Rapamycin). This TOR-centric model believes Rapamycin, and other rapalogs like it, can be an aid in the treatment of age and disease prevention in humans. When taken in a prescribed dosage , rapamycin and similar analogs, not only can but most certainly will extend the life-span a a healthy adult. However this theory has been ridiculed by opponents and anonymous peer-reviewers, it was predicted in 2008 that all the nay-sayers of the theory would, in five years, “be taking the TOR-centric model for granted”, in which this prediction has been proven correct.

It was actually in 2006 when rapamycin was first approved for its clinical use and was made readily available for immediate use. Rapamycin can be used in the treatment of cancer, cardiovascular and autoimmune diseases, also metabolic disorders, and other diseases of aging from osteoporosis to Alzheimer’s. It has been found for rapamycin to be the most effective if it’s used as an anti-aging drug, to slow down senescence and for disease prevention. Rapamycin is safe enough to be administered to transplant patients on a daily dosage. It has been found that rapamycin “eliminates hyper-immunity rather than suppressing immunity.”Rapamycin is safe enough for daily, oral consumption, it is non-toxic and well suitable. Studies done both preclinical and clinical have proven that it has promising use for age-related diseases, it has “anti-tumor, bone-sparing, calorie restriction-mimicking side effects.” After further review has been done on rapamycin, it has been proven that it has life-extending agents to produce immunostimultory activities when administered in the proper dosages. It is truly a wonder drug in the treatment of aging and disease prevention.

Cancer Treatment Centers of America-Professionals Who Care

In conjunction with NantHealth and Allscripts, Cancer Treatment Centers of America is putting in place a system that will give NantHealth access to the Electronic Health Record that is enabled by Allscripts Sunrise. This will help the Clinical Pathways Program keep information current in the cancer treatment process. All available Treatment options are presented through Clinical Pathways and it allows doctors to avoid possible guesswork and ambiguous decisions, since they are constantly being presented with new oncology research. Clinical Pathways helps combine all the latest information available in Cancer Research with the priority given to the patient. This gives patients a wide range of options to choose from with treatments that are geared for each individual.
What makes the blogĀ https://www.myctca.com/ unique is that the professionals there aren’t treating a host of different conditions. They treat only one thing – cancer, and they strive to give each patient personalized care. With locations in Atlanta, Tulsa, Chicago, Phoenix, and Philadelphia, the physicians at Cancer Treatment Centers of America take the time to get to know the patient so they can develop an individualized treatment plan. This includes therapies to help the patient manage the side effects of treatment, maintain their strength and stamina, and quality of life.
In the hospitals of CTCA, the standard theraphies of radiation, chemotherapy, surgery, and immunotherapy are used, along with innovative methods of treating and managing depression, anxiety, nausea, fatigue, and pain. Cancer Treatment Centers of America presently has their headquarters in Boca Raton, Florida, after having been originally based in Schaumburg, Illinois.

For further information follow CTCA on Facebook.

Dr. Clay Siegall Is Achieving Great Things Through Seattle Genetics

Dr. Clay Siegall is the co-founder of the ever growing cancer research and development facility Seattle Genetics. The company was established in 1998. He serves as the Chairman of the Board, President, and CEO. He created Seattle Genetics with the hopes of developing new cancer drugs that would help treat patients that were not responding well to other forms of treatment. Dr. Clay Siegall is a scientist that has worked with some of the most notable cancer research and development companies. Adcetris is the companies most widely used creation and is an antibody-drug conjugate. It was approved for use by the FDA in 2011. The Takeda Pharmaceutical Company was key in helping to create this now globally available cancer treatment drug.

Dr. Clay Siegall has managed to provide superior leadership which has enable the company to obtain several licenses for ADC technology with many pharmaceutical giants.These licenses have helped the company generate over $350 million. Seattle Genetics currently has over 20 ADCs in the final phase of testing and will be available for use in the near future. In total, Seattle Genetics has raised over $1.2 billion in funding through their fundraising efforts. This includes both public and private funds.

Before co-founding Seattle Genetics, Dr. Clay Siegall worked for the National Cancer Institute, Bristol-Myers Squibb, and the Pharmaceutical Research Institue. He developed his scientific knowledge of cancer treatments and research techniques while working at these major companies. He knew that he wanted to make a difference through cancer treatment development which spurred him to create Seattle Genetic. Serving in an executive capacity for the facility has helped them achieve a great deal of success since they began in 1998. They are working hard to create new treatments that will help people that suffer from specific types of cancer that might not respond well the available treatments that are currently on the market. He has also served in an executive capacity for many other facilities in addition to winning many prestigious awards. He also is an accomplished author having written over seventy publications. He also holds fifteen patents. He attended the University of Maryland where he attained his B.S. in Zoology. He later went on the receive a Ph.D. from George Washington University in Genetics.